App-Quantinova.ai

Pre-Transplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Chronic Portal Vein Thrombosis

B. Thornburg - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Impact of Anatomic Variation and Reconstructive Technique on Complications Following Living Liver Donor Transplantation - A Report from the A2ALL Consortium

T. Baker - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Increased Ratio of Estimated Spleen/Graft Volume Is a Strong Predictor of Posttransplant Portal Hypertension in Adult-To-Adult Living Donor Liver Transplantation: Significance of Splenectomy On Portal Venous Pressure and Patient Survival

S. Mizuno - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Resolution of Glomerular Fibrin Thrombi in Deceased Donor Kidneys

R. Batra - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Preformed IgA Antibodies to B2-Glycoprotein Is an Indepedent Risk Factor for Graft Thrombosis and Early Graft Loss After Renal Transplantation

J. Morales - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Association Between Polymorphisms of PPM1E Gene and Tumor Size of Hepatocellular Carcinoma Patients

M.-S. Park - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Fibrinogen (IV)

Characteristics and Outcomes of Patients With Incidental Hepatocellular Carcinoma Detected in the Explanted Liver Following Transplant

M. Goh - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Alfa-fetoprotein

Should we advocate a structured venous access policy in adults with CF?

K. Colpaert - European Cystic Fibrosis Conference (ECFC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Pathological analysis of native liver in cystic fibrosis (CF) with severe portal hypertension reveals a vascular liver disease without cirrhosis

S. Hillaire - European Cystic Fibrosis Conference (ECFC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Venous thrombosis

N/A

Thrombo-embolic disease in CF patients: Difficult to diagnose, difficult to treat

J. Pirson - European Cystic Fibrosis Conference (ECFC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Heparin

Long-term safety and maintenance of analgesia with an extended-release hydrocodone tablet formulated with OraGuard technology during a 12-month open-label study in patients with chronic pain

M. Hale - American Pain Society (APS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

hydrocodone

Pharmacotherapy for VAD Thrombus: Response Rates and Financial Impact of Anticoagulant Strategies

Lynne Sylvia - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Oxidative Stress Induced Modulation of Platelet Integrin ?IIb?3 Expression and Shedding During Major Bleeding in Heart Failure Patients Supported By Continuous Flow Left Ventricular Assist Devices

Nandan K. Mondal - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Superoxide dismutase

Bridging Anticoagulation After CF-LVAD Implantation

Indra Bole - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Clinical Characteristics of Patients with Suspected Left Ventricular Assist Device Thrombosis Who Respond to Intensified Anticoagulation

Demetrios G. Doukas - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Socioeconomic Status May be a Marker of Risk for Clinical Outcomes with Continuous Flow Ventricular Assist Devices

Mustafa Ahmed - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Early Elevated Pump Power and Associated Hemolysis Amongst HeartMate II Left Ventricular Assist Devices

Anjan Tibrewala - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Discharge Glomerular Filtration Rate (GFR) as a Predictor of Outcomes Post Left Ventricular Assist Device Placement

Burhan Mohamedali - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

HeartMate II to HVAD Device Exchange: What Can We Learn?

Kershaw V. Patel - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Anticoagulation Intensity and Thrombotic or Bleeding Outcomes in Outpatients with Continuous Flow Left Ventricular Assist Devices

Michael E. Nassif - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Filters

7277 Abstracts